Short answer
Septerna, Inc. (SEPN) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results and business highlights announced for quarter ended June 30, 2026.
Septerna, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results and business highlights announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the detailed financial and operating information
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 revenue $26.7M, driven by Novo Nordisk collaboration amortization, milestones, and $11.2M research services
- Net loss narrowed to $13.0M from $24.8M, despite R&D increasing to $35.1M
- Cash, equivalents and marketable securities $516.5M, supporting operations at least into 2029
- SEP-479 half-life approximately three to four days supports potential once-daily dosing; SAD/MAD data expected Q1 2027
- SEP-631 Phase 2b CSU study replaced by capital-efficient signal-finding strategy, reducing near-term development spending but delaying pivotal progression
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Septerna, Inc. 8-K filings
Get the next SEPN 8-K as it lands
Follow SEPN for push alerts, or ask the research agent what this filing means.